Japan

Celaid Therapeutics Raises ¥1.05B for Stem Cell Growth

Celaid Therapeutics Inc. announced that it successfully completed the first close of its Series B financing. It raised JPY 1.055 billion, which is about USD 7.2 million. This funding came from venture capital firms and the Japan Agency for Medical Research and Development (AMED). Celaid has raised a total of JPY 2.52 billion (USD 17.14 million), including grants and subsidies. The funding shows increasing confidence in Celaid's main program, CLD-001. This is an innovative therapy using ex vivo-expanded hematopoietic stem cells (HSCs) for severe pediatric non-malignant diseases. CLD-001 shows good promise in preclinical models. It has effective safety and notable advancements in cell manufacturing and CMC. The company is advancing toward a U.S. FDA pre IND filing. Celaid is also developing its proprietary HSC expansion platform through collaborations, including with…